APHRIA INC ORDINARY SHARES CANADA (OTCMKTS:APHQF) on Focus After Report of Less Shorts

September 16, 2018 - By Mark Babin

The stock of APHRIA INC ORDINARY SHARES CANADA (OTCMKTS:APHQF) registered a decrease of 44.11% in short interest. APHQF’s total short interest was 5.75M shares in September as published by FINRA. Its down 44.11% from 10.29 million shares, reported previously. With 5.33M shares average volume, it will take short sellers 1 days to cover their APHQF’s short positions.

The stock increased 12.76% or $1.695 during the last trading session, reaching $14.9816. About 4.18M shares traded or 167.44% up from the average. Aphria Inc. (OTCMKTS:APHQF) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Aphria Inc. produces, supplies, and sells medical cannabis in Canada. The company has market cap of $3.51 billion. The firm offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It has a 110.97 P/E ratio. It also provides support services in the form of medical consultations, group therapies, and rehabilitation to veteran and first responders.

More notable recent Aphria Inc. (OTCMKTS:APHQF) news were published by: Seekingalpha.com which released: “The CannaGuide: Complete Cannabis Coverage – Aphria Part 1 – Full Operations, Partnerships, And Investments …” on August 23, 2018, also Seekingalpha.com with their article: “Aphria: Moving On After Molson Fallout, What’s Next?” published on September 07, 2018, Investorplace.com published: “3 Canadian Marijuana Stocks With Reasonable Valuations” on September 05, 2018. More interesting news about Aphria Inc. (OTCMKTS:APHQF) were released by: Midasletter.com and their article: “Aphria Inc Unjustly Hit By Well Known Mainstream News Outlet” published on August 20, 2018 as well as Midasletter.com‘s news article titled: “VIDEO: Liberty Health Sciences Inc (CNSX:LHS) Success in Florida Market” with publication date: September 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.